NBRVF — Nabriva Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$1.64m
- $36.94m
Annual income statement for Nabriva Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.66 | 9.48 | 5.03 | 28.9 | 36.9 |
| Cost of Revenue | |||||
| Gross Profit | — | 9.41 | 4.26 | 15.7 | 8.35 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 124 | 89 | 73.9 | 77.4 | 92.4 |
| Operating Profit | -114 | -79.5 | -68.9 | -48.5 | -55.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -115 | -82.7 | -69.3 | -49 | -55.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -115 | -82.8 | -69.5 | -49.5 | -57.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -115 | -82.8 | -69.5 | -49.5 | -57.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -115 | -82.8 | -69.5 | -49.5 | -57.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -565 | -279 | -132 | -28.5 | -20.3 |